ÌÇÐÄvlog

[Skip to Navigation]
Sign In

November 2024, Vol 10, No. 11, Pages 1477-1600

Original Investigation

Inpatient Care and Outcomes Among People With Cancer Experiencing Homelessness

Abstract Full Text
JAMA Oncol. 2024;10(11):1503-1510. doi:10.1001/jamaoncol.2024.3645

This cross-sectional study of data from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project National Inpatient Sample investigates whether housing status is associated with the receipt of inpatient care and outcomes among hospitalized adults with cancer who are experiencing homelessness.

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

Abstract Full Text
has audio
JAMA Oncol. 2024;10(11):1511-1518. doi:10.1001/jamaoncol.2024.3651

This cross-sectional study examines clinicogenomic features of Lynch syndrome and characterizes responses to immune checkpoint blockade therapy.

Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival

Abstract Full Text
JAMA Oncol. 2024;10(11):1519-1529. doi:10.1001/jamaoncol.2024.3666

This single-center cohort study examines the association of molecular, socioeconomic, and clinical covariates with race and ethnicity disparities in overall survival among patients with colorectal cancer.

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2024;10(11):1532-1536. doi:10.1001/jamaoncol.2024.3891

This nonrandomized clinical trial examines the safety and efficacy of guanylate cyclase-C (GCC) chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer.

Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer

Abstract Full Text
JAMA Oncol. 2024;10(11):1537-1547. doi:10.1001/jamaoncol.2024.4006

This prospective case-control study nested in 3 large, well-established, prospective US cohorts examines whether the oral bacterial and fungal microbiome is associated with subsequent head and neck squamous cell cancer risk.

Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma

Abstract Full Text
JAMA Oncol. 2024;10(11):1548-1553. doi:10.1001/jamaoncol.2024.4085

This cohort study examines 3-year survival among patients with hepatocellular carcinoma placed on a watch-and-wait protocol after achieving complete remission with combined locoregional therapy and immunotherapy.

Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer

Abstract Full Text
JAMA Oncol. 2024;10(11):1554-1560. doi:10.1001/jamaoncol.2024.4318

This retrospective cohort study assesses the prognostic value of the Fracture Risk Assessment Tool (FRAX) for incident fractures in patients with cancer.

Brief Report

Cervical Cancer Incidence in the US-Affiliated Pacific Islands

Abstract Full Text
JAMA Oncol. 2024;10(11):1561-1564. doi:10.1001/jamaoncol.2024.3675

This cross-sectional study examines the population-based incidence of cervical cancer in 6 US-Affiliated Pacific Islands from 2007 to 2020.

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2024;10(11):1565-1570. doi:10.1001/jamaoncol.2024.3900

This nonrandomized clinical trial evaluates the safety, pharmacokinetics, and preliminary efficacy of rogaratinib in combination with the programmed cell death 1 ligand 1 inhibitor atezolizumab in cisplatin-ineligible patients with FGFR messenger RNA–positive, locally advanced/metastatic urothelial cancer.

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2024;10(11):1571-1575. doi:10.1001/jamaoncol.2024.3089

This randomized clinical trial examines whether stereotactic body radiotherapy improves local control compared with hypofractionated conventional radiotherapy.

Research Letter

Frequency of ERBB2-Low Expression in Endometrial Cancer

Abstract Full Text
open access
JAMA Oncol. 2024;10(11):1587-1588. doi:10.1001/jamaoncol.2024.3660

This study reanalyzes epidermal growth factor receptor 2 (ERBB2) data from a previous study to characterize patient subgroups with ERBB2-low tumors.

Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants

Abstract Full Text
JAMA Oncol. 2024;10(11):1588-1590. doi:10.1001/jamaoncol.2024.3683

This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.

Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2024;10(11):1590-1593. doi:10.1001/jamaoncol.2024.4000

This randomized clinical trial compares the effect of transperineal vs transrectal prostate biopsy on infection rates after biopsy.

Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2024;10(11):1593-1595. doi:10.1001/jamaoncol.2024.4342

This cohort study examines the institution-level and patient-level factors associated with mismatch repair and microsatellite testing for individuals with colorectal cancer.

Review

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2024;10(11):1578-1584. doi:10.1001/jamaoncol.2024.3679

This review analyzes the heterogeneity of residual disease after neoadjuvant systemic therapy in patients with breast cancer.

JAMA Oncology Clinical Challenge

Recurrent Fevers in a Patient With Splenomegaly

Abstract Full Text
has active quiz
JAMA Oncol. 2024;10(11):1585-1586. doi:10.1001/jamaoncol.2024.4029

A 36-year-old man presented with 10 weeks of recurrent fevers, malaise, night sweats, unintentional weight loss, and dyspnea. What is your diagnosis?

Viewpoint

Active Surveillance for Low-Risk Cancer—The Waiting Is the Hardest Part

Abstract Full Text
JAMA Oncol. 2024;10(11):1491-1492. doi:10.1001/jamaoncol.2024.2667

This Viewpoint describes the benefits and challenges of active surveillance as a clinical approach to monitor low-risk cancers with favorable prognoses.

Accrual to Radiotherapy Trials in the US—Pitfalls and Potential Solutions

Abstract Full Text
JAMA Oncol. 2024;10(11):1493-1494. doi:10.1001/jamaoncol.2024.3663

This Viewpoint discusses accrual difficulties of radiotherapy cooperative group trials and proposes solutions.

Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria

Abstract Full Text
JAMA Oncol. 2024;10(11):1495-1496. doi:10.1001/jamaoncol.2024.3888

This Viewpoint discusses how the inclusion or exclusion of certain events in the standardization of clinical trial end points can affect the interpretation of results.

How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?

Abstract Full Text
JAMA Oncol. 2024;10(11):1497-1498. doi:10.1001/jamaoncol.2024.3909

This Viewpoint explores how guideline groups can come together to agree on a framework that produces clear and unified recommendations.

Invited Commentary

Contributions to Colorectal Cancer Disparities

Abstract Full Text
JAMA Oncol. 2024;10(11):1530-1531. doi:10.1001/jamaoncol.2024.3516

Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2024;10(11):1576-1577. doi:10.1001/jamaoncol.2024.2905
Cancer Care Chronicles

Persons With Cancer Rather Than Cancer Patients—Semantics Matter

Abstract Full Text
JAMA Oncol. 2024;10(11):1499-1500. doi:10.1001/jamaoncol.2024.3642

This essay describes a physician’s shift to patient-focused language in treatment of patients with cancer.

Poetry and Oncology

Heartbreaker

Abstract Full Text
JAMA Oncol. 2024;10(11):1600. doi:10.1001/jamaoncol.2024.3912
Comment & Response

Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2024;10(11):1595-1596. doi:10.1001/jamaoncol.2024.4211

Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non–Small Cell Lung Cancer—Reply

Abstract Full Text
JAMA Oncol. 2024;10(11):1596-1597. doi:10.1001/jamaoncol.2024.4214

Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses

Abstract Full Text
JAMA Oncol. 2024;10(11):1597. doi:10.1001/jamaoncol.2024.4324

Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses—Reply

Abstract Full Text
JAMA Oncol. 2024;10(11):1597-1598. doi:10.1001/jamaoncol.2024.4327
Correction

Error in Figure 1

Abstract Full Text
free access
JAMA Oncol. 2024;10(11):1598. doi:10.1001/jamaoncol.2024.4797

Error in Byline

Abstract Full Text
free access
JAMA Oncol. 2024;10(11):1598. doi:10.1001/jamaoncol.2024.5097
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2024;10(11):1477. doi:10.1001/jamaoncol.2023.4668
×